[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA83240C2 - Ингибиторы каспази, которые содержат изоксазолиновое кольцо - Google Patents

Ингибиторы каспази, которые содержат изоксазолиновое кольцо

Info

Publication number
UA83240C2
UA83240C2 UAA200602050A UAA200602050A UA83240C2 UA 83240 C2 UA83240 C2 UA 83240C2 UA A200602050 A UAA200602050 A UA A200602050A UA A200602050 A UAA200602050 A UA A200602050A UA 83240 C2 UA83240 C2 UA 83240C2
Authority
UA
Ukraine
Prior art keywords
caspase inhibitors
inhibitors containing
isoxazoline ring
containing isoxazoline
same
Prior art date
Application number
UAA200602050A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хьє-Кьюн Чанг
Йеонг-Соо Ох
Чеол-Вон Парк
Йонг-Джін Джанг
Тае-Кйо Парк
Сунг-Суб Кім
Мін-Джунг Кім
Мі-Джеонг Парк
Джунг-Гью Парк
Хи-Донг Парк
Кьєонг-Сік Мін
Тае-Соо Лі
Санг-Кьюн Лі
Соо-Хьєон Кім
Хі-Кьюнг Джеонг
Сун-Хва Лі
Хва-Донг Кім
Ае-Рі Кім
Кі-Соок Парк
Хьюн-Ік Шин
Хьєон-Воок Чой
Кью-Воонг Лі
Джае-Хоон Лі
Тае-Хо Хео
Хо-Джун Кім
Тае-Сік Квон
Original Assignee
Елджі Лайф Саєнсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елджі Лайф Саєнсез Лтд. filed Critical Елджі Лайф Саєнсез Лтд.
Publication of UA83240C2 publication Critical patent/UA83240C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Изобретение касается: изоксазолинового производного, которое может служить ингибитором разнообразных каспаз; способа получения такого производного; и терапевтического состава, который содержит такое производное, для предотвращения воспаления и апоптоза.
UAA200602050A 2003-08-27 2004-08-26 Ингибиторы каспази, которые содержат изоксазолиновое кольцо UA83240C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030059451 2003-08-27
PCT/KR2004/002139 WO2005021516A1 (en) 2003-08-27 2004-08-26 Caspase inhibitors containing isoxazoline ring

Publications (1)

Publication Number Publication Date
UA83240C2 true UA83240C2 (ru) 2008-06-25

Family

ID=36102769

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200602050A UA83240C2 (ru) 2003-08-27 2004-08-26 Ингибиторы каспази, которые содержат изоксазолиновое кольцо

Country Status (27)

Country Link
US (1) US7557133B2 (ru)
EP (1) EP1660464B1 (ru)
JP (1) JP4503017B2 (ru)
KR (1) KR100594544B1 (ru)
CN (1) CN1842521B (ru)
AP (1) AP2104A (ru)
AR (1) AR045503A1 (ru)
BR (1) BRPI0413848B8 (ru)
CA (1) CA2535711C (ru)
EA (1) EA012080B1 (ru)
EC (1) ECSP066378A (ru)
EG (1) EG25751A (ru)
HK (1) HK1092788A1 (ru)
IL (1) IL173638A (ru)
MA (1) MA27999A1 (ru)
MX (1) MXPA06002267A (ru)
MY (1) MY162110A (ru)
NO (1) NO335620B1 (ru)
NZ (1) NZ545216A (ru)
OA (1) OA13244A (ru)
PE (1) PE20050371A1 (ru)
TR (1) TR200600899T2 (ru)
TW (1) TWI346110B (ru)
UA (1) UA83240C2 (ru)
UY (1) UY28494A1 (ru)
WO (1) WO2005021516A1 (ru)
ZA (1) ZA200601586B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774999B1 (ko) * 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
US7754909B1 (en) * 2005-04-06 2010-07-13 The Florida State University Research Foundation, Inc. Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20080042290A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리돈 구조를 포함하는 캐스파제 저해제
CN101778833A (zh) 2007-08-10 2010-07-14 日本曹达株式会社 含氮杂环化合物和有害生物防除剂
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
AU2009250295B2 (en) 2008-05-21 2014-05-01 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2691379B1 (de) 2011-03-31 2016-11-02 Bayer Intellectual Property GmbH Herbizid und fungizid wirksame 3-phenylisoxazolin-5-carboxamide und 3- phenylisoxazolin-5-thioamide
DK2697246T3 (en) 2011-04-15 2018-05-28 Genesis Tech Limited SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
PL2900644T3 (pl) * 2012-09-25 2017-03-31 Bayer Cropscience Ag Skuteczne chwastobójczo i grzybobójczo 5-oksy-podstawione 3-fenyloizoksazolino-5-karboksamidy i 5-oksy-podstawione 3-fenylo-izoksazolino-5-tioamidy
CN104797577B (zh) * 2012-09-25 2018-01-12 拜尔农作物科学股份公司 除草和杀真菌活性的3‑杂芳基‑异噁唑啉‑5‑甲酰胺和3‑杂芳基‑异噁唑啉‑5‑硫代酰胺
CN104812739B (zh) * 2012-09-25 2017-12-12 拜尔农作物科学股份公司 具有除草作用的3‑苯基异噁唑啉衍生物
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−5−カルボキサミド化合物および有害生物防除剤
JP2017515854A (ja) 2014-05-12 2017-06-15 クオナトウス ファーマシューティカルズ,インコーポレイテッド カスパーゼ阻害剤による慢性肝疾患の合併症の治療
CN105753853B (zh) 2014-12-16 2020-08-04 沈阳中化农药化工研发有限公司 一种含异恶唑啉的脲嘧啶类化合物及其用途
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
CA3010286A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
BR112019005985A2 (pt) 2016-10-05 2019-06-25 Novartis Ag composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
EP3572402B1 (en) * 2017-01-23 2022-05-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Linked cyclic compound as caspase inhibitor
ES2894278T3 (es) 2017-06-13 2022-02-14 Bayer Ag 3-Fenilisoxazolin-5-carboxamidas de amidas de ácido tetrahidro- y dihidrofuranocarboxílico con efecto herbicida
PL3638665T3 (pl) 2017-06-13 2021-12-27 Bayer Aktiengesellschaft Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy kwasów i estrów tetrahydro- i dihydrofuranokarboksylowych
EP3668845B1 (de) 2017-08-17 2024-06-26 Bayer Aktiengesellschaft Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern
UA127418C2 (uk) 2018-01-25 2023-08-16 Баєр Акціенгезельшафт Гербіцидно активні 3-фенілізоксазолін-5-карбоксамідні похідні циклопентилкарбонової кислоти
PL3937637T3 (pl) 2019-03-12 2023-08-07 Bayer Aktiengesellschaft Herbicydowo czynne 3-fenyloizoksazolino-5-karboksyamidy estrów kwasów cyklopentenylokarboksylowych zawierających S
CN113710666A (zh) * 2019-04-19 2021-11-26 株式会社Lg化学 半胱天冬酶抑制剂的前药
US20220227743A1 (en) * 2019-04-30 2022-07-21 Lg Chem, Ltd. Prodrug of caspase inhibitor
KR102366226B1 (ko) * 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
TW202237143A (zh) 2020-12-10 2022-10-01 南韓商Lg化學股份有限公司 酸(Boronic Acid)化合物
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
CN114908028B (zh) * 2022-04-19 2024-05-31 杭州师范大学 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
JP2818820B2 (ja) * 1993-11-26 1998-10-30 ファイザー・インク. 抗炎症剤としての3−アリール−2−イソオキサゾリン類
ATE154932T1 (de) 1993-11-26 1997-07-15 Pfizer Isoxazolinverbindungen als entzündungshemmende mittel
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
AU5762899A (en) * 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor
AU7322300A (en) * 1999-09-17 2001-04-24 Lg Chem Investment Ltd. Caspase inhibitor

Also Published As

Publication number Publication date
NO20061362L (no) 2006-03-24
AR045503A1 (es) 2005-11-02
UY28494A1 (es) 2005-02-28
MA27999A1 (fr) 2006-07-03
PE20050371A1 (es) 2005-08-17
AU2004268895A1 (en) 2005-03-10
WO2005021516A1 (en) 2005-03-10
BRPI0413848B1 (pt) 2019-04-30
NZ545216A (en) 2009-06-26
US7557133B2 (en) 2009-07-07
KR20050022364A (ko) 2005-03-07
US20060223848A1 (en) 2006-10-05
TWI346110B (en) 2011-08-01
EP1660464B1 (en) 2015-02-25
NO335620B1 (no) 2015-01-12
BRPI0413848A (pt) 2006-10-24
OA13244A (en) 2007-01-31
CA2535711A1 (en) 2005-03-10
ECSP066378A (es) 2006-08-30
MXPA06002267A (es) 2006-05-17
CN1842521A (zh) 2006-10-04
EP1660464A1 (en) 2006-05-31
CA2535711C (en) 2011-07-05
IL173638A0 (en) 2006-07-05
JP2007503429A (ja) 2007-02-22
HK1092788A1 (en) 2007-02-16
EA012080B1 (ru) 2009-08-28
EG25751A (en) 2012-06-25
BRPI0413848B8 (pt) 2021-05-25
KR100594544B1 (ko) 2006-06-30
ZA200601586B (en) 2007-05-30
EP1660464A4 (en) 2008-11-26
EA200600465A1 (ru) 2006-08-25
IL173638A (en) 2011-12-29
MY162110A (en) 2017-05-31
TW200512199A (en) 2005-04-01
CN1842521B (zh) 2012-09-05
TR200600899T2 (tr) 2006-09-21
AP2104A (en) 2010-02-06
JP4503017B2 (ja) 2010-07-14
AP2006003509A0 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
UA83240C2 (ru) Ингибиторы каспази, которые содержат изоксазолиновое кольцо
YU5503A (sh) Nesteroidni supresori zapaljenja
HK1093064A1 (en) Thienopyrimidine derivatives as potassium channel inhibitors
AU2002316437A1 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
MXPA06000407A (es) Isomero c cci-779.
AU2003293356A8 (en) Dihydropyridinone derivatives as hne inhibitors
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
TW200513461A (en) Organische verbindungen
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
EP1545509A4 (en) CASPASE HEMMER AS CANCER
TW200730190A (en) New combination to treat liver fibrosis
UA96269C2 (ru) Ингибиторы цистеинпротеазы и их терапевтическое применение
AU1142502A (en) Novel crystalline forms of a factor xa inhibitor
TW200509921A (en) Alkaline salts
AU2003248710A1 (en) Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
AU2003264707A1 (en) Use of a chrysanthellum extract
GB0226550D0 (en) Organic compounds
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
GEP20064009B (en) Cetylpyridinium salt of an anti-inflammatory agent and armaceutical compositions containing it
SI1358182T1 (en) Diazocine derivates and their use as tryptase inhibitors
JO2569B1 (en) Unprecedented pyrazoloperimidones and their uses to inhibit phosphodiesterase